Home » Stocks » VERU

Veru Inc. (VERU)

Stock Price: $8.50 USD 0.08 (0.95%)
Updated Jun 21, 2021 1:04 PM EDT - Market open
Market Cap 670.94M
Revenue (ttm) 50.03M
Net Income (ttm) -476,205
Shares Out 75.18M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE 117.65
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $8.50
Previous Close $8.42
Change ($) 0.08
Change (%) 0.95%
Day's Open 8.47
Day's Range 8.33 - 8.59
Day's Volume 179,882
52-Week Range 2.30 - 24.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

--VERU-100 formulated to address the clinical limitations of currently available androgen deprivation therapy-- --The Phase 2 clinical trial is expected to be completed by 2H calendar 2021--

1 week ago - GlobeNewsWire

Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent, in heavily pre-treated breast cancer pa...

2 weeks ago - Benzinga

-- In Phase 2 study, enobosarm, an oral selective androgen receptor (AR) agonist, had the most significant antitumor effects in heavily pretreated AR+ER+ metastatic breast cancer subjects with ≥ 40% AR ...

2 weeks ago - GlobeNewsWire

-- Sabizabulin, an oral selective cytoskeleton disruptor, demonstrated good safety, significant evidence of antitumor efficacy, and that chronic administration is feasible in ongoing Phase 1b/2 study of...

2 weeks ago - GlobeNewsWire

MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today...

3 weeks ago - GlobeNewsWire

-- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeti...

4 weeks ago - GlobeNewsWire

Veru Inc (NASDAQ: VERU) has enrolled the first patient in its Phase 3 clinical trial evaluating sabizabulin (VERU-111) in high-risk hospitalized COVID-19 patients. Sabizabulin an oral cytoskeleton disru...

1 month ago - Benzinga

—Sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities—

1 month ago - GlobeNewsWire

Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and -7.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Veru Inc (NASDAQ: VERU) reported a Q1 EPS loss of ($0.04), which met the analyst consensus estimate. The loss is wider than ($0.01) net loss a year ago.

1 month ago - Benzinga

Shares of Veru (NASDAQ:VERU) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share fell 300.00% over the past year to ($0.04), which were in line with the estim...

1 month ago - Benzinga

-- First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients-- --New Drug Application Accepted for Review by FDA for Propriet...

1 month ago - GlobeNewsWire

Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of patients who have failed estrogen blocking agents a...

1 month ago - Benzinga

MIAMI, May 05, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today...

1 month ago - GlobeNewsWire

MIAMI, April 21, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, tod...

2 months ago - GlobeNewsWire

Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Palisade's Dan Veru on the market reaction to Fed leaving rates unchanged

YouTube video

Dan Veru, Co-Chairman and Chief Investment Officer of Palisade Capital Management, joins Worldwide Exchange to discuss the pullback in stocks after the Fed's decision to leave rates where they are.

3 months ago - CNBC Television

MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, tod...

3 months ago - GlobeNewsWire

Veru Inc (NASDAQ: VERU) has engaged Morgan Stanley as a financial advisor to pursue strategic alternatives for its legacy Female Healthcare Business. "Furthermore, with the potential for five registrati...

3 months ago - Benzinga

MIAMI, March 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast canc...

3 months ago - GlobeNewsWire

MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, tod...

3 months ago - GlobeNewsWire

Veru (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Veru Inc (NASDAQ: VERU) will start testing VERU-111 in the registrational Phase 3 study in hospitalized patients who have COVID-19 virus infection and are at high risk for Acute Respiratory Distress Syn...

3 months ago - Benzinga

Veru Inc (NASDAQ: VERU) has submitted a 505(b)(2) New Drug Application with the FDA for TADFIN (tadalafil 5mg and finasteride 5mg) capsules, daily oral dosing combination formulation, for the treatment ...

3 months ago - Benzinga

--TADFIN™, Tadalafil 5mg and Finasteride 5mg formulated capsule, for daily oral dosing to improve compliance-- --Administration of Tadalafil and Finasteride is more effective than Finasteride alone to t...

3 months ago - GlobeNewsWire

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hospit...

Other stocks mentioned: NVTA, CYH, MTEM
4 months ago - Benzinga

The stock price of Veru Inc. , a biopharmaceuticals company focused on oncology medicines, has seen a monstrous 112% rise over the last ten trading days, while it's up 47% over the last five trading day...

4 months ago - Forbes

Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of approximately $100 million. Underwriters have an option to purchase up t...

4 months ago - Benzinga

MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, anno...

4 months ago - GlobeNewsWire

MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, anno...

4 months ago - GlobeNewsWire

Female Health Company The (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...

4 months ago - Zacks Investment Research

Shares of Veru (NASDAQ:VERU) moved higher by 17.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 60.00% year over year to ($0.02), which beat the...

4 months ago - Benzinga

--Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter-- --Late Clinical Stage Oncology Drug Pipeline Focused on Prostate and...

4 months ago - GlobeNewsWire

Analysts are excited about the potential of the biotech's experimental COVID-19 treatment.

4 months ago - The Motley Fool

Dr. Mitchell Steiner, chief executive of drugmaker Veru, said a Phase 2 trial of VERU-111 showed an 82% relative reduction in Covid-19 patient mortality versus placebo.

4 months ago - CNBC

Veru CEO says cancer drug has potential to prevent Covid-19 deaths

YouTube video

Veru CEO Dr. Mitchell Steiner explained how VERU-111, a prostate cancer drug developed by the biotech company, could be used as an anti-inflammatory and antiviral treatment to help patients diagnosed wi...

4 months ago - CNBC Television

The company reported great results from a phase 2 study in treating hospitalized COVID-19 patients.

4 months ago - The Motley Fool

Veru Inc (NASDAQ: VERU) rises sharply after announcing positive efficacy and safety results from a Phase 2 trial evaluating VERU-111 versus placebo in approximately 40 hospitalized patients at high risk...

4 months ago - Benzinga

– Potential for two-pronged action against COVID-19 as an antiviral and  anti-inflammatory agent supported by Phase 2 clinical study results –

4 months ago - GlobeNewsWire

Female Health Company The (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, toda...

4 months ago - GlobeNewsWire

After a stellar 3x rise since the March 23 levels of last year, at the current price of around $10 per share we believe Veru Inc. stock, a biopharmaceuticals company focused on oncology medicines, has r...

5 months ago - Forbes

MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, toda...

5 months ago - GlobeNewsWire

Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Shares of Veru Inc. soared 51.4% toward a seven-year high on massive volume, after the biopharmaceutical company announced positive results from a Phase 2 study of its treatment of breast cancer. Tradin...

6 months ago - Market Watch

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific upd...

Other stocks mentioned: ANPC, ARPO, ARVN, SYBX
6 months ago - Benzinga

Veru (VERU) stock is doing well on Monday after announcing positive news from a Phase 2 clinical trial of its breast cancer drug. The post VERU Stock News: 9 Things for Investors to Know About Veru Brea...

6 months ago - InvestorPlace

Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

About VERU

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2... [Read more...]

Industry
Biotechnology
IPO Date
Jul 19, 1990
CEO
Mitchell Steiner
Employees
339
Stock Exchange
NASDAQ
Ticker Symbol
VERU
Full Company Profile

Financial Performance

In 2020, Veru Inc.'s revenue was $42.59 million, an increase of 33.92% compared to the previous year's $31.80 million. Losses were -$18.97 million, 57.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Veru Inc. stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is an increase of 170.59% from the latest price.

Price Target
$23.00
(170.59% upside)
Analyst Consensus: Strong Buy